Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ASN 2026
Finerenone in Patients with CKD by SGLT2 Inhibitor Treatment: A FIND-CKD Analysis
In this prespecified subgroup analysis of the FIND-CKD trial, finerenone reduced total eGFR decline, UACR, and the risk of kidney and CV outcomes versus placebo in participants with nondiabetic CKD
- Treatment effects of finerenone in SGLT-2i users were consistent with the overall FIND-CKD trial; there was no evidence of heterogeneity between SGLT-2i users and non-users
- Adverse event profiles did not differ according to SGLT-2i use at baseline
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
